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Colorectal cancerAn abundance ofmicroﬁbril-associated glycoprotein 3-like (MFAP3L) signiﬁcantly correlateswith distantmetas-
tasis in colorectal cancer (CRC), although themechanism has yet to be explained. In this study, we observed that
MFAP3L knock-down resulted in reduced CRC cell invasion and hepatic metastasis. We evaluated the cellular lo-
cation and biochemical functions of MFAP3L and found that this proteinwas primarily localized in the nucleus of
CRC cells and acted as a protein kinase. When EGFR translocated into the nucleus upon stimulation with EGF,
MFAP3L was phosphorylated at Tyr287 within its SH2 motif, and the activated form of MFAP3L phosphorylated
ERK2 at Thr185 and Tyr187. Moreover, the metastatic behavior of CRC cells in vitro and in vivo could be partially
explained by activation of the nuclear ERKpathway throughMFAP3L phosphorylation. Hence,we experimentally
demonstrated for theﬁrst time thatMFAP3L likely participates in the nuclear signaling of EGFR and ERK2 and acts
as a novel nuclear kinase that impacts CRC metastasis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Microﬁbril-associated protein 3-like (MFAP3L) is a microﬁbril-
associated glycoprotein (MAGP). MAGPs are non‐ﬁbrillin, microﬁbrillar
proteins that comprise the structure of microﬁbrils. It is well accepted
that MAGPs bind to distinct regions of ﬁbrillin and facilitate microﬁbril-
lar assembly. Although no known human disease is linked directly to
MAGP genes, recent evidence has implicated the involvement of
MAGPs in tumorigenesis. For instance, several groups observed that
MAGP2 (MFAP5) expression is increased in different human cancer
tissues and cancer cell lines. In head and neck cancer, high MAGP2 ex-
pression is accompanied by poor survival [1]. In ovarian cancer cells,
MAGP2 serves as a prognostic indicator of prolonged tumor cell survival
and increased endothelial cell motility [2–4]. Thus, MAGPs are thought
to promote the acquisition of the vascular phenotype requisite for
tumor growth and metastasis, although the detailed mechanisms have
not been clearly elucidated.86 10 8812 2437.
s, Chinese Academy of Sciences,
1, China . Tel./fax:+86 10 8409
iqiliu@big.ac.cn (S. Liu).Our group observed, for the ﬁrst time, that MFAP3L was up-
regulated in primary tumor tissues of colorectal cancer (CRC) patients
and that this expression closely correlated with distant metastasis.
Based on the results of proteomics and immunohistochemistry analy-
ses,we previously proposed that theprotein signature ofMFAP3L, phos-
phorylated IκBα and TNFα could be used as a reference to estimate
hepatic metastasis risk in CRC patients [5]. This conclusion was recently
conﬁrmed in another study, in which a set of molecular biomarkers,
including EGFR, MFAP3L and CapG, exhibited high sensitivity and spec-
iﬁcity for predicting colorectal liver metastasis [6]. MFAP3L was ﬁrst
cloned from the human testicular cDNA library, and its abundance in
adult testis was found to be ten-fold higher than in embryonic testis
[7]. The MFAP3L gene is localized at 4q32.3 and consists of two exons
within a 15-kb genomic region. Its full-length mRNA sequence contains
1345 bp, and its protein sequence consists of 409 amino acids.
Using cDNA microarrays and Southern blots, Xiao et al. found that the
MFAP3L gene is highly expressed in the human testis and prostate
and is expressed at a low level in the colon and ovary. In addition,
bioinformatic analysis of theMFAP3L gene suggests a single-pass mem-
brane proteinwith a trans-membrane domain at 150–172 aa, several N-
glycosylation sites in the extracellular region and a cluster of proximal
phosphorylation sites, which are similar to kinases such as tyrosine ki-
nases, PKC and casein kinase II [7]. There is also a conserved SH2 motif
at 279–294 aa that contains a potential EGFR phosphorylation site
(NetphosK 1.0 Server). The proximity of this potential phosphorylation
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EGFR signaling pathway.
It is well known that EGF-induced signaling is associatedwith tumor
invasion and metastasis [8]. Its receptor, EGFR, is a typical protein tyro-
sine kinase, and activated EGFR phosphorylates downstream proteins
containing SH2-domains, leading to cascading effects on several signal-
ing pathways andmore aggressive tumor cell behaviors [9]. The ligand-
dependent nuclear translocation of EGFR has recently been detected in
various cancer cells and clinical cases [10,11]. In addition, the accumula-
tion of nuclear EGFR, especially its phosphorylated form, closely
correlates with poor clinical outcomes, such as advanced TNM stage,
metastasis and limited postoperative survival [12,13]. Because there is
a positive correlation between MFAP3L abundance and CRC metastasis,
andMFAP3L contains a conserved SH2motif that is potentially targeted
by EGFR,we sought to determinewhether the phosphorylation status of
MFAP3L acts as a regulatory factor of CRC metastasis.
To explore the biological functions and mechanisms of MFAP3L
involved in cancer metastasis, we ﬁrst adopted an RNAi technique to
verify MFAP3L involvement in CRC invasion and metastasis. We then
investigated MFAP3L cellular localization and whether it exhibited ki-
nase activity in vivo. Based on confocal microscopy and immunoblotting
experiments, MFAP3Lwas shown to be primarily localized in the nucle-
us and to act as a substrate of nuclear-translocated EGFR. Furthermore,
activated MFAP3L served as a kinase that phosphorylated ERK2 at
Tyr187.MFAP3L over-expression triggered the ERK cascade, which pro-
moted the expression of ERK-regulated genes and augmented colon
cancer cell metastasis and invasion. Thus, our results demonstrate that
MFAP3L is an active element of the nuclear EGFR signaling pathway
and the process of CRC metastasis.
2. Materials and methods
2.1. Materials and antibodies
A total of 57 colorectal carcinoma samples were collected at the Bei-
jing Cancer Hospital, Beijing, China. Carcinoma samples were obtained
from the core tumor focus, and matched normal adjacent samples
were collected 5 cm away from the tumor tissues. The macroscopic
pathological features and microscopic histological classiﬁcations were
reviewed by a senior pathologist. All tissue samples were approved for
research projects by the Research Ethical Committee of Beijing Cancer
Hospital. EGF, AG1478, U0126, myelin basic protein (MBP; bovine)
and a protease inhibitor cocktail were purchased from Sigma. The
following antibodies were purchased from Santa Cruz: EGFR; MEK1;
ERK2; cathepsin D; MMP2; osteopontin, actin; lamin A; aldehyde
reductase (AR); phosphorylated EGFR (Tyr1045); phosphorylated ERK
(Tyr204); and p-Tyr (PY99). The following antibodies were purchased
from SAB: cMyc-tag; ELK1; phosphorylated ELK1 (Ser389); and phos-
phorylated ERK (Thr202). The polyclonal antibody targeting phosphor-
ylated MFAP3L (Tyr287) is commercially available through SAB. To
obtain the polyclonal antibody for MFAP3L, we immunized rabbits
with recombinant truncated MFAP3L protein, which contained
the N-terminal 103 amino acids. SW480, SW620 and CHO cells were
obtained from the American Type Culture Collection (ATCC). Cells
were maintained in Dulbecco's modiﬁed Eagle's medium containing
100 U/mL penicillin, 100 mg/mL streptomycin and 10% FBS.
2.2. Molecular cloning and plasmid construction
The full-length CDS regions of humanMFAP3L, ERK2 and EGFRwere
ampliﬁed by PCR from the cDNA library of the human testis. The intra-
cellular domain (669–1210) of EGFR (EGFR-ICD) was ampliﬁed using
the template for full-length EGFR, and all fragments were cloned into
the pcDNA3.1/myc-His vector. The dominant-positive (DP; Y287D)
and dominant-negative (DN; Y287A)mutants ofMFAP3L, the pNLSmu-
tant (RRR669-671AAA) of EGFR and the dominant-negative mutant(Y187F) of ERK2 were generated using a QuikChange Site-Directed
Mutagenesis Kit (Stratagene). His-tagged recombinant proteins of
wild-type and mutant MFAP3L and ERK2, as well as EGFR-ICD, were
expressed in Escherichia coli BL21 DE3 cells using the pET28a vector
and puriﬁed by Ni-afﬁnity chromatography. The digestion sites for
the expression vectors for MFAP3L, EGFR and ERK2 were as follows:
BamHI/Hind III, NheI/Hind III and NdeI/XhoI, respectively. The spe-
ciﬁc RNAi vectors for MFAP3L and ERK2 were constructed using
pSilencerTM 3.1-H1 neo (Life Technologies). The target DNA sequences
for MFAP3L were 5′-GCATCTACGGCACCGTGAAC-3′ and 5′-GGCATTTG
AGATCGCCAAG-3′ and for ERK2 was 5′-GGAAAAGCTCAAAGAACTA-3′;
these sequences have previously been veriﬁed [14].
2.3. Cell transfection
Two colon cancer cell lines, SW480 and SW620, were cultured in
complete DMEM (Invitrogen) containing 10% fetal bovine serum (FBS;
Thermo Fisher), penicillin (100 kU/L) and streptomycin (100 mg/L) at
37 °C in a humidiﬁed atmosphere containing 5%CO2. A Chinese hamster
ovary cell line (CHO)was cultured in F12medium (Invitrogen) contain-
ing 5% FBS (Thermo Fisher) at 37 °C in a humidiﬁed atmosphere con-
taining 5% CO2. All transfections were performed using Lipofectamine
2000 (Invitrogen), and empty vectors were transfected as negative con-
trols. For transient transfection, the cells were harvested after 24–48 h
for use in subsequent experiments. For the selection of stable cells,
following a 1-month selection period using 600 μg/ml G418, the
existing clones were examined through western blot analyses.
2.4. MTT, scratch wound healing and Transwell invasion assays
Cell proliferationwasmeasured using the 3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide (MTT) assay. Approximately 2000 cells
were plated in each well of a 96-well plate and grown for 0, 1, 2 or
3 days. At 4 h before the end of the incubation, 10 μL of MTT (5 mg/mL)
was added to each well followed by 100 μL of DMSO, and the samples
were mixed to dissolve the crystals. The reaction products were de-
tected using a spectrometer at 570/630 nm. The result of each time
point represented three independent replicates. Cell migration was ex-
amined using the scratch wound healing assay. Cells were grown to
conﬂuence in 60-mm culture dishes. A sterile pipette tip was used to
scratch a 1-mm-wide wound along the center of the dish, and the de-
marcated wound area was imaged using an inverted Nikon microscope
at various times after wounding (0, 12 and 24 h). Cell invasion was de-
tected using Transwell invasion assay. Twenty-ﬁve thousand cells were
suspended in a culture mediumwithout serum and plated in the upper
chambers (BD BioCoat™Matrigel Invasion Chambers in 24-well plates,
BD Biosciences), and the bottomwells were ﬁlled with NIH3T3 cell cul-
ture medium. After 24 h, the inserts were washed with PBS, the non-
migratory cells were removed with cotton swabs, and the ﬁlters were
collected for HE staining. Ten ﬁelds of view were counted under an
inverted Nikon microscope, and, for each cell type, three independent
experiments were performed to calculate the average number of
stained cells.
2.5. Hepatic metastasis model in nude mice
The tested cells were suspended in Hank's solution, and 2 × 106 cells
were injected into the spleens of 5-week old female BalB/c nude mice.
The mice were anesthetized and placed on their right sides, and their
spleens were exposed through a 5–7 mm cut on the left ﬂank. Cells
were injected into the middle of the spleen using a tuberculin syringe
with a 26G needle. The mice were maintained according to the
guidelines of the National Institutes of Health for the Care and Use of
Laboratory Animals. The mice were sacriﬁced 7 weeks after the opera-
tion, and the liver and spleen tissues were evaluated through necropsy.
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Cells were washed with pre-chilled PBS and homogenized in buffer
containing 210 mM sucrose, 70 mM mannitol, 1 mM EDTA, 1 mM
PMSF, 1.5 mMMgCl2 and 10 mMHEPES. Nuclear and non-nuclear frac-
tions were prepared with differential centrifugation. Nuclei were
pelleted at 1000×g for 10min, and the non-nuclear fractionwas obtain-
ed after centrifugation at 16,000 ×g for 10 min as a supernatant. The
sample was lysed in buffer containing 8 M urea, 4% CHAPS, 0.5%
Pharmalyte (pH 3–10 L, GE), 10 mM DTT, 1 mM PMSF and 2 mM EDTA.
The lysate was electrophoresed using SDS-PAGE and electrotransferred
onto a PVDF membrane. The PVDF membrane was incubated with
antibodies and visualized with an ECL kit using the ImageQuant ECL
system (Bio-Rad).
2.7. Immunoﬂuorescence and confocal microscopy
Cells were ﬁxed with 3.7% formaldehyde for 15 min and perme-
abilizedwith 0.2% Triton X-100 for 6min. PBS containing 1%BSAwas in-
cubatedwith the cells for 1 h at room temperature to block non-speciﬁc
binding, and primary antibodies at a dilution of 1:100 in blocking buffer
were incubated with the cells for 2 h. After thorough washing with
0.05%TritonX-100 in PBS, the cellswere incubatedwith the appropriate
FITC-conjugated secondary antibodies at a dilution of 1:100 in blocking
buffer for 1 h. Fluorescent images were acquired using a confocal laser-
scanning microscope (Zeiss LSM510) and analyzed with the LSM5
Image Browser program (Carl Zeiss Micro-Imaging). For a reference of
organelle localization, DAPI was used to stain the nucleus.
2.8. Immunohistochemical staining
The colorectal carcinoma andmatched normal samples for immuno-
histochemical (IHC) stainingwere collected at the Beijing Cancer Hospi-
tal in Beijing, China. The carcinoma samples were obtained from the
core tumor focus, and the matched normal samples were collected
5 cm away from the tumor tissues. IHC staining was performed using
an EnVision™+ Kit (Dako). The tissue slices were incubated with the
primary antibody against MFAP3L at a dilution of 1:50 overnight at
4 °C. In the negative control group, 1% bovine serum albumin was
used instead of the primary antibody.
2.9. Immunoprecipitation
Whole cell and nuclear lysateswere prepared in lysis buffer contain-
ing 50 mM HEPES (pH 7.4), 150 mM NaCl, 1% NP40, 1 mM EDTA, 10%
glycerol and 2% protease inhibitor cocktail. Onemilligram of each lysate
was precleared by incubation of protein A beads boundwith pre-serum
for 2 h. After centrifugation at 1000 ×g for 5min, the supernatants were
transferred to the slurry containing 2 μg of antibody and protein A beads
for overnight incubation. After thorough washing with lysis buffer, the
immunoprecipitated complexes bound to the protein A beads were
dissolved in SDS loading buffer and detected by western blot analysis
or LC MS/MS.
2.10. Pull-down assay
One milligram of whole cell or nuclear lysate was prepared in
lysis buffer containing 50 mM HEPES (pH 7.4), 100 mM NaCl, 1%
NP40, 25 mM imidazole, 1 mM EDTA, 10% glycerol and 2% protease
inhibitor cocktail and precleared by incubation with Ni-NTA beads
for 2 h. After centrifugation at 500 ×g for 5 min, the supernatants
were incubated with 40 mg of recombinant MFAP3L protein and
Ni-NTA beads overnight. After thorough washing with lysis buffer,
the protein complexes were dissolved in SDS loading buffer and de-
tected by western blot analysis.2.11. In vitro kinase assay
Five micrograms of recombinant MFAP3L or MBP protein, 1 μg of re-
combinant ERK2, or the product precipitated by the cMyc-tag orMFAP3L
antibody was incubated with 0.5 μg of recombinant ERK2 in 20 μL of ki-
nase assay buffer containing 50 mM Tris (pH 7.5), 10 mMMgCl2, 1 mM
DTT, 0.1 mM sodium orthovanadate, 40 μg/mL PS, 30 μg/mL DAG and
0.1 mM unlabeled ATP for 30 min at 30 °C. The reaction was halted by
the addition of SDS loading buffer, and the phosphorylation status was
detected by autoradioactivity (6 h at−80 °C) or western blot analysis.
2.12. Identiﬁcation of phosphorylation sites using mass spectrometry
To identify the phosphorylation sites of the substrates, the corre-
sponding bands on SDS-PAGE gels weremanually excised and subjected
to in-gel digestion with trypsin (Promega) at 37 °C overnight. The
digested products were identiﬁed by LC MS/MS using an UltiMate 3000
Nano HPLC system (Dionex) and a three-dimensional high-capacity ion
trap mass spectrometer (Esquire HCTplus, Bruker Daltonics). MASCOT-
compatible ﬁles were created using Data Analysis 3.3 software (Bruker
Daltonics), and searches were performed using MASCOT software
(version 2.2.04, Matrix Science) with the latest human or bovine NCBI
database. All searches were performed with tryptic speciﬁcity, allowing
for one missed cleavage. Oxidation of methionine and phosphorylation
of tyrosine, serine and threoninewere considered variablemodiﬁcations.
MS2 spectra acquired with the ion trap instrument were generally
accepted with a MASCOT cutoff score of 20 and a mass tolerance of
0.4 Da for the MS and MS2 experiments. Additionally, the identiﬁcation
results were reproducible across parallel injections as well as sample
preparations.
2.13. Statistical analyses
The SPSS 14.0 software was used for statistical analyses (SPSS,
Chicago, IL, USA). Student's t-test was used to compare the values
between subgroups, and p b 0.05 was considered to represent a sig-
niﬁcant difference between groups of data.
3. Results
3.1. MFAP3L knock-down inhibits CRC cell metastasis
MFAP3L expression levels correlate with CRC distant metastasis ac-
cording to a previous report using a proteomic survey [5]. In the present
study, we ﬁrst attempted to identify whether CRC metastasis was asso-
ciatedwith changes inMFAP3L abundance in cancer cells. Two different
RNAi sequences targeting MFAP3L, 5′-GCATCTACGGCACCGTGAAC-3′
and 5′-GGCATTTGAGATCGCCAAG-3′, were cloned into pSliencerTM 3.1-
H1 neo, designated as pSi1 and pSi2, respectively. These two RNAi
vectors were then transfected into SW620 colon cancer cells, which
demonstrate a high metastatic potential, and stable cell lines were se-
lected. Fig. 1a shows that the knock-down effect of pSi2 was more efﬁ-
cient than that of pSi1. Thus, pSi2 SW620 cells, designated as MF−,
were used for the following experiments. Compared with control
SW620 cells transfected with the non-targeting (NT) construct, the
MF− cells exhibited a clear reduction in growth rate as measured
by the MTT assay (Fig. 1b). In addition, migration and invasion, as in-
dicated by the scratch wound healing and Transwell assays, respec-
tively, of MF− cells were reduced compared with NT cells (Fig. 1c
and d, p b 0.001). Furthermore, we employed a commonly accepted
mouse model to study hepatic metastasis in vivo by injecting MF− or
NT cells into the spleens of nude mice (7 mice/group) and monitoring
the frequency of liver metastasis based on tumor formation in the
liver. In theNT group, 4mice developed splenic tumors (57%), and 5 de-
veloped hepatic metastasis (71%), while in the MF− group, 2 mice de-
veloped splenic tumors (29%), and none acquired hepatic metastasis
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Fig. 1.MFAP3L knock-down inhibits colon cancer cell metastasis. a,MFAP3L knock-down in SW620 cells. NT, pSi1 and pSi2 indicate the empty vector and two different RNAi vectors, respec-
tively. Western blot analysis was performed to detect the effect of RNAi. b–d, MFAP3L knock-down reduced the growth, migration and invasion capabilities of SW620 cells. MTT, scratch
wound healing (SWH) and Transwell invasion assays were performed using MFAP3L knock-down cells (MF−) and control cells (NT). For the MTT assay, the result of each time point
represents three replicates. For the SWH assay, ﬁve ﬁelds of view for each cell line were observed, and a representative view is shown. For the Transwell assay, ten views were counted,
and three independent experimentswere performed to calculate the average. All above tests were conducted in triple bio-replication. e,MFAP3L knock-down inhibited tumorigenesis and
hepatic metastasis in SW620 cells. Seven mice were injected with either NT or MF− cells; representative images of splenic tumorigenesis and hepatic metastasis are shown.
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regulation of CRC metastasis.
3.2. MFAP3L is mainly localized in the nucleus
To elucidate howMFAP3L participates in CRCmetastasis, we sought
to determineMFAP3L localizationwithin cellular organelles. Cells stably
overexpressing MFAP3L were established through transfection of
pcDNA3.1-MFAP3L-myc-His into SW480 cells, denoted as MF+ cells,
and the empty vector was transfected into SW480 cells, denoted as
EV+ cells. The images acquired from confocal microscopy indicated
that MFAP3L primarily accumulated in the nucleus and was slightlydistributed in the cytoplasm and plasma membrane (Fig. 2a). A similar
result was observed in CHO cells (Fig. 3e). MFAP3L localization was
also examined in MF+ cells through cellular fractionation and western
blot analysis. As illustrated in Fig. 2b, MFAP3L was strongly immuno-
recognized in the nuclear fraction, whereas it was only slightly detected
in the non-nuclear fraction. Moreover, the nuclear localization of
MFAP3Lwas observed in the IHC images of 57 CRC tissues and their nor-
mal adjacent tissues. The nuclear localization of MFAP3L was detected
in almost 80% of the CRC tissues showing positive MFAP3L staining
(24 out of 31 cases, Fig. 2c) and could not be observed in 5 normal adja-
cent samples showing positive MFAP3L staining. Nuclear-localized
MFAP3L was alsomore signiﬁcantly expressed in CRC tissues compared
Fig. 2.MFAP3L is mainly localized in the nucleus. a–b, The majority of MFAP3L protein was localized in the nucleus. Immunoﬂuorescence (IF) and nuclear fractionation (NF) assays were
performed to detect MFAP3L localization in MFAP3L-overexpressing SW480 cells (MF+) and control cells (EV+). DAPI staining was used to mark the nucleus in the IF assay, and
Lamin A and AR were used as indicators of the nucleus and cytosol, respectively, in the NF assay. c, MFAP3L showed nuclear localization in human CRC tissue samples. IHC staining
was performed to detect MFAP3L localization in human CRC tissues and matched normal samples.
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results were in good agreementwith our previous observations and sug-
gested that MFAP3L was likely distributed in the nucleus in vivo. There-
fore, we concluded that MFAP3L is a predominantly nuclear protein.
3.3. Nuclear translocation of EGFR directly phosphorylates MFAP3L at
Tyr287
MFAP3L contains a potential EGFR phosphorylation site. Experimen-
tally, MFAP3L was found to be primarily localized in the nucleus, and
EGFR is generally found to be translocated to the nucleus in cancer
cells. We thus sought to examine whether nuclear MFAP3L is a target
of nuclear-translocated EGFR. To address this question, we ﬁrst treated
MF+ cells with EGF and collected nuclear and non-nuclear fractions
at different times after EGF stimulation. As shown in Fig. 3a, both
EGFR and phosphorylated EGFR in the nuclear fraction were greatly
increased within 1 h of EGF induction, indicating that EGFR nuclear
translocation occurred in MF+ cells. Utilizing an in vitro kinase assay,
we sought to determine whether EGFR directly reacted with MFAP3L.
Western blot analysis (Fig. 3b) revealed that the truncated recombinant
EGFR with its intracellular domain (ICD) speciﬁcally phosphorylated
MFAP3L, while the MS spectrum (Fig. 3b) demonstrated that Tyr287
of MFAP3L was phosphorylated by EGFR. We further generated a
dominant-negative mutant of MFAP3L (DN; Y287A) and examined its
phosphorylation status in the presence of EGFR. The data presented in
Fig. 3b revealed no phosphorylation of Tyr287 in DN cells, suggesting
that Tyr287 ofMFAP3Lwas an accessible site for EGFR phosphorylation.
We next addressed whether EGFR could phosphorylate MFAP3L in vivo
by treating MF+ and EV+ cells with EGF and monitoring the phos-
phorylation status of MFAP3L by western blot analysis using anantibody against pTyr287 of MFAP3L at various intervals following
EGF treatment. As shown in Fig. 3c, in EV+ cells with a low level of
MFAP3L expression, pTyr287 of MFAP3L was almost undetectable,
whereas inMF+cells with a high level ofMFAP3L expression, pMFAP3L
was clearly enhanced after a 1-h EGF treatment. In addition, a faint
pMFAP3L signal could be detected in MF+ cells even without EGF
treatment, implying that there were other endogenous kinases that
phosphorylated MFAP3L. This result suggested that the phosphoryla-
tion of MFAP3L by EGFR in vivo was in good agreement with its ob-
served behavior in vitro. To conﬁrm EGFR-mediated phosphorylation
ofMFAP3L,we performedexperimentswithAG1478, a speciﬁc EGFR ty-
rosine kinase inhibitor. As shown in Fig. 3d, AG1478 treatment clearly
inhibited the increased pTyr287 levels of MFAP3L in MF+ cells after a
1-h stimulation with EGF, which indicated that MFAP3L was phosphor-
ylated by EGFR in these cells.
In contrast to SW480 cells, which possess a lower abundance of
MFAP3L protein and a higher abundance of EGFR protein, we selected
CHO cells, which demonstrate low constitutive EGFR expression and
high endogenous MFAP3L expression, to address whether nuclear-
translocated EGFR was capable of phosphorylating MFAP3L in vivo. We
established CHO cells that stably over-expressed wild-type EGFR
(EGFR+) or an EGFRmutant (pNLS+), which lacked a nuclear localiza-
tion signal (RRR669-671AAA) [15]. Upon EGF treatment, wild-type
EGFR translocated to the nucleus, whereas no nuclear translocation of
pNLS+ was detected (Fig. 3e). Importantly, the two forms of EGFR
maintained a similar tyrosine phosphorylation status under EGF
treatment, indicating that the two EGFRs shared comparable kinase ac-
tivities. As shown in Fig. 3f, pTyr287 of MFAP3L was only up-regulated
in EGFR+ but not pNLS+ cells, convincingly demonstrating that
nuclear-translocated EGFR could phosphorylate MFAP3L in vivo.
Fig. 3. EGFR phosphorylates MFAP3L through nuclear translocation. a, EGFR phosphorylation and nuclear translocation were enhanced upon EGF treatment in MF+ cells. The nuclear and
non-nuclear fractions of MF+ cells treated with 100 ng/ml EGF for 1 h were collected for western blot analysis to detect EGFR translocation and phosphorylation status. The time points
of EGF treatment were 0, 30 min, 1 h, 2 h and 5 h. Lamin A and AR were used as markers of the nucleus and cytosol, respectively. b, EGFR directly phosphorylated MFAP3L at Tyr287. An
in vitro kinase assay was performed by incubating 100 ng of the recombinant intracellular domain (ICD) of EGFR with 1 μg of theWT or DNmutant of MFAP3L. MFAP3L phosphorylation
was detected using the pTyr antibody, and the phosphorylation site was identiﬁed by LCMS/MS. c,Western blot analysis of pTyr287 of MFAP3L and pERK2 in EV+ andMF+ cells treated
with EGF (100 ng/mL). The time points included 0, 30 min and 1 h. d, Western blot analysis was used to determine the effect of an EGFR inhibitor on pTyr287 of MFAP3L. pEGFR was
detected using an antibody against pTyr1045 of EGFR. AG1478 was used to pretreat the cells at 10 μM for 1 h, and then EGF (100 ng/mL) was added for an additional 1 h. All cells treated
with EGF and/or AG1478were starved in serum-freemediumfor 24h, andwater andDMSOwere added asmock controls for EGF andAG1478 treatment, respectively. e, The localization of
EGFR and MFAP3L in CHO cells expressing wild-type (EGFR+) and a mutant lacking the nuclear localization signal (pNLS+) of EGFR. An immunoﬂuorescence assay was performed to
detect the distributions of EGFR andMFAP3L in the cells. All cells were treatedwith EGF for 1 h. f, pTyr287 ofMFAP3Lwas enhanced onlywhen EGFR accumulated in the nucleus.Western
blot analysis was performed to determine the phosphorylation levels of EGFR and MFAP3L in EGFR+, pNLS + and EV cells treated with EGF for 1 h.
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Bioinformatic analysis revealed that MFAP3L possesses a glycine-
rich stretch of residues in the vicinity of the lysine residue in the
N-terminus (98–101 aa) and aspartic acid residues in the central re-
gion (282–284, 302–304, 332–333 aa), which are the common featuresof the catalytic domain of protein kinases. To determine whether there
was any measurable protein kinase activity for MFAP3L, we designed
two experiments to identify the binding proteins of MFAP3L in vivo
and to speciﬁcally examine its substrate afﬁnity. The proteins that
bound to MFAP3L in the nucleus of MF+ cells were enriched through
IP using the cMyc-tag antibody followed by protein identiﬁcation with
1429X. Lou et al. / Biochimica et Biophysica Acta 1842 (2014) 1423–1432LCMS/MS (Fig. 4a). Based on our stringent criterion, a total of six unique
proteins were identiﬁed that could be localized in or translocated to the
nucleus (Table 1). Of these candidate substrates, ERK2, a member ofFig. 4.MFAP3L binds and phosphorylates ERK2 at Tyr187 in the nucleus. a, An IP assay using an an
proteins bound to MFAP3L were identiﬁed by LC MS/MS. b-c, MFAP3L was found to bind to ER
nuclear extracts of MF+ and EV+ cells. c, A pull-down assaywas performed using 40mg of rec
expression ofMFAP3L reduced and enhanced the phosphorylation of ERK at Thr 185 and Tyr187
kinase assay of MFAP3L with wild-type (WT) ERK2. Different amounts of recombinant MFAP3
MFAP3L with WT ERK2 and dominant-negative mutants (T185A, Y187F and T185A/Y187F)
MBP (5 μg; 20 kDa) was detected through autoradiography after protein separation on a 15%
phosphorylation byMFAP3Lwas independent of theMEKpathway. TheMEK inhibitor U0126 (1
for western blot analysis.MAP kinase family, is commonly reported to be involved in tumorigen-
esis and metastasis. We further conﬁrmed the speciﬁc interaction
between MFAP3L and ERK2 using another approach, whereby theti-myc-tag antibody was performed using the nuclear extracts of MF+ and EV+ cells. The
K2 in the nucleus. b, An MFAP3L IP was performed using an anti-myc-tag antibody for the
ombinantHis-taggedMFAP3Lwith SW480 cell nuclear extracts. d, Knock-down and over-
, respectively.MF+, EV+,MF− andNT cellswere used forwestern blot analysis. e, In vitro
L were analyzed for their effect on ERK2 phosphorylation (1 μg). f, In vitro kinase assay of
of ERK2 and its substrate bovine MBP. The phosphorylation of ERK2 (1 μg; 40 kDa) and
SDS-PAGE gel, and the phosphorylation site of MBP was identiﬁed by LC MS/MS. g, ERK2
2.5 μM)was used to treatMF+and EV+ cells for 24 h, and the cell lysateswere harvested
Table 1
The binding proteins of MFAP3L identiﬁed by LC MS/MS.
Description Accession No. pI MW Identiﬁed peptides Nuclear localization Function annotation
Nup93 gi|116242684 5.5 94 NADKVLELMNK, LVPLNQESVEER Y Component of the nucleoporin complex
Lamin A/C gi|119573381 9.0 79 RTPTPSSLCPSTR, LLEGEEERLR Y Components of the nuclear envelope
NONO gi|34932414 9.0 54 LFVGNLPPDITEEEMRK,
FGQAATMEGIGAIGGTPPAFNR
Y DNA and RNA binding protein
Paraneoplastic 62 kDa antigen gi|119609629 6.4 47 MYSTNEEQVQEIEYLTK, IHGLTETIER Y Nuclear protein binding
ERK2 gi|228860 6.7 40 FRHENIIGINDIIR,
YTNLSYIGEGAYGMVCSAYDNVNK
Translocation from
cytosol
MAP kinase activity
Histone H2A gi|12654707 11.1 14 VGAGAPVYLAAVLEYLTAEILELAGNAAR
NDEELNKLLGK Y Core component
of nucleosome
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were analyzed by western blot using appropriate antibodies. In the
anti-cMyc IP product, immune-recognition signals for MFAP3L and
ERK2 were detected in MF+ cells, but not in EV+ cells, while in the
His-MFAP3L pull-down product, a positive immune-recognition signal
for ERK2 was found (Fig. 4b and c). Hence, these results were in agree-
ment with our conclusions drawn from the MS data.
It is well known that the biological functions of ERK2mainly rely on
its phosphorylation status and nuclear translocation, although ERK2 has
not yet been reported as the substrate of a nuclear kinase. In addition,
the complete activation of ERK2 requires its phosphorylation at both
Thr185 and Tyr187 in its TXY motif [16]. To determine whether
MFAP3L can phosphorylate ERK2, we used two antibodies that speciﬁ-
cally recognize pThr185 and pTyr187 of ERK2 tomonitor the phosphor-
ylation status of ERK2 in vivo. As depicted in Fig. 4d, the two
phosphorylation events of ERK2 at Thr185 and Tyr187 were clearly at-
tenuated in MF− cells compared with NT cells, and these events were
clearly enhanced in MF+ cells compared to EV+ cells, suggesting that
the level of MFAP3L correlated with ERK2 phosphorylation at Thr185
and Tyr187. We then explored whether MFAP3L could directly catalyze
ERK2 phosphorylation. In an in vitro experiment, we generated the fol-
lowing recombinant proteins: MFAP3L; wild-type (WT) ERK2; and the
dominant-negative mutants (T185A, Y187F and T185A/Y187F) of
ERK2. The western blot images shown in Fig. 4e and the autoradiogra-
phy data shown in Fig. 4f (Lanes 5–7) revealed that the phosphorylation
levels of ERK2 at Thr185 and Tyr187 were proportional to the concen-
tration of MFAP3L in the reaction mixtures. Fig. 4f (Lanes 2–4) shows
that ERK2 phosphorylation was clearly reduced in the mutants T185A
and Y187F and completely lost in double mutant (T185A/Y187F).
These results demonstrated that MFAP3L could phosphorylate ERK2 at
Thr185 and Tyr187.
To further address whether MFAP3L activates ERK2, bovine myelin
basic protein (MBP), a common substrate of ERK2, was incorporated
into the kinase assay. Fig. 4f (Lanes 5–7) revealed that the phosphoryla-
tion status of MBP was proportional to the MFAP3L concentration and
the extent of ERK2 phosphorylation. In addition, the phosphorylation
ofMBP at Thr97, a common site phosphorylated by ERK2,was identiﬁed
through LC MS/MS (Fig. 4f) [17]. Furthermore, MBP phosphorylation
was clearly decreased with the Y187F mutant and completely lost
with the T185A and T185A/Y187F mutants (Fig. 4f, Lanes 2–4). These
data suggested that the phosphorylation of ERK2 at Thr185 catalyzed
by MFAP3L could activate this kinase, while phosphorylation at
Tyr187 was required for a higher level of activation. This observation
was generally in agreement with a previous report concerning ERK2
activation [16], and these results led us to conclude that MFAP3L acts
as a dual kinase that can directly phosphorylate ERK2.
ERK2 activation is generally regulated by the cytoplasmic MEK
pathway [18]. To determine whether the MEK pathway impacts the
phosphorylation of ERK2 by MFAP3L, we used U0126, a speciﬁc MEK
inhibitor, to examine the function of MFAP3L as a kinase in the absence
of MEK pathway activity. When MF+ and EV+ cells were treated with
U0126 for 24 h, pERK2 expression was completely lost in EV+ cells,whereas pERK2 appeared consistently in MF+ cells (Fig. 4g). These
results suggest that the kinase activity of MFAP3L is independent of
the cytoplasmic MEK pathway.3.5. MFAP3L activates the ERK2 cascade and enhances colon cancer cell
invasion
Because nuclear ERK2 could be phosphorylated by MFAP3L, we
next inquired whether the ERK2-related pathway would be activated
in the presence of overexpressed MFAP3L. To address this question,
we established two stable SW480 cell lines with overexpression of the
dominant-positive mutant (DP; Y287D) and the dominant-negative
mutant (DN; Y287A) of MFAP3L. Then, we conducted a comparison
experiment in EV+, MF+, DP and DN cells to examine the activation
status of the ERK2 pathway and the expression status of the genes
regulated by the ERK2 pathway. The phosphorylation status of ELK1
was selected as a marker of the activated ERK2 pathway. As shown in
Fig. 5a, compared with the other studied cells, DP cells showed the
highest phosphorylation levels of ERK2 and ELK1 and the highest
levels of cathepsin D, MMP2 and osteopontin, which are commonly
up-regulated by the ERK pathway during metastasis [11,16,19,20]. In
contrast to EV+ cells, a remarkably higher phosphorylation level of
ELK1 and expression level of cathepsin D, MMP2 and osteopontin was
detected in MF+ cells, likely due to ERK2 phosphorylation, whereas
these biological events were not observed in the DN cells, as the
Y287A mutant cannot phosphorylate ERK2 and activate the ERK path-
way. Correspondingly, in Transwell assays, the DP cells displayed the
highest invasion capacity compared with the other cell types, while
MF+ cells exhibited a relatively higher invasion capacity than EV+
and DN cells (Fig. 5b, p b 0.001). These results indicate that pTyr287 of
MFAP3L is required for its kinase activity and activation of the ERK path-
way. Moreover, the activation of the ERK pathway in the nucleus in-
duced by MFAP3L highly correlated with the invasion capacity of the
cancer cells. In addition, when ERK2 expression was knocked-down
through RNAi in DP cells, ERK2 phosphorylation and the invasion
capacity of the DP cells were dramatically attenuated (Fig. 5c and d;
p b 0.001). This experimental evidence led us to conclude that
MFAP3L signiﬁcantly activates the ERK2 pathway; in turn, ERK2 phos-
phorylation promotes a higher expression of metastasis-related genes,
resulting in CRC metastasis and invasion.
ERK2 phosphorylation and activation are generally induced by EGF
through EGFR and the cytoplasmic RAS/RAF/MEK pathway, with tran-
sient responses observed within a period of less than 1 h [18]. Because
MFAP3L is phosphorylated by nuclear EGFR, and ERK2 is a phosphoryla-
tion substrate of EGFR signaling or MFAP3L (Fig. 3c), we analyzed the
contribution of MFAP3L to ERK2 activation. In EV+ cells, which showed
lower MFAP3L expression, the signal for ERK2 phosphorylation was
temporarily enhanced by EGF treatment and attenuated within 1 h.
However, in MF+ cells, which showed a higher abundance of MFAP3L,
pERK2 was clearly increased within 30 min, without attenuation for at
least 1 h (Fig. 3c). Therefore, under EGF/EGFR induction, MFAP3L is likely
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Fig. 5.MFAP3L activates the ERK2 cascade and enhances the invasion of colon cancer cells. a,Western blot analysis to determine the activation status of the ERKpathway in EV+,MF+,DPand
DN cells. b, d, Transwell invasion assay using EV+,MF+, DP and DN cells, DP cells with transient ERK2 RNAi (DP/ERK2-) and control cells. For the Transwell assay, ten ﬁelds of viewwere
counted, and three independent experiments were performed to calculate the average. c, Western blot analysis to determine whether the ERK pathway was inhibited by transient ERK2
RNAi in DP cells.
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tively converting dephosphorylated ERK2 to pERK2 in the nucleus.
4. Discussion
In this study, we provided evidence that MFAP3L is a novel member
of the nuclear EGFR signaling pathway and possesses protein kinase ac-
tivity that can phosphorylate ERK2 at Thr185 and Tyr187. Accordingly,
MFAP3L phosphorylation in the nucleus is an important inducer that
enhances CRC invasion and metastasis. Due to its nuclear localization
and the enhanced expression and phosphorylation of MFAP3L in CRC
tissues and cells, this new protein kinase may be considered a novel
protein biomarker, especially regarding the application of antibodies
targeting MFAP3L for IHC analysis. In addition, EGFR inhibitors are
widely used in therapies for cancer, including CRC. Based on our obser-
vation, MFAP3L is likely to play a key role in nuclear EGFR signaling, and
the regulation of MFAP3L kinase activity may therefore have pharma-
ceutical effects on tumor progression.
Based on NCBI Blast results, MFAP3L showed 71% homology to
microﬁbrillar-associated protein 3 (MFAP3). Further alignment analysis
revealed that these two proteins demonstrate poor homology with any
other known protein, including the othermembers of theMAGP family,
which are components of microﬁbrils in the extracellular matrix of
many tissues [21]. Thus, MFAP3L may function differently from other
members of the MAGP family. Based on our bioinformatic analysis
and experiments with MFAP3L protein, we noted several interestingobservations. For instance, although the bioinformatic analysis predict-
ed that MFAP3L contains a single-pass transmembrane domain, our ex-
perimental results indicated that this protein was not located at the
plasmamembrane but was rather primarily in the nucleus. Because nu-
clear proteins generally display hydrophobic features, the potential
transmembrane domain of MFAP3L may facilitate its interactions with
components of the nuclear membrane. Our bioinformatic analysis
further predicted that MFAP3L contains protein sequences similar to
those commonly found in the catalytic domains of protein kinases, al-
though MFAP3L does not possess an intact classical catalytic domain.
Our experimental results, nevertheless, demonstrated that MFAP3L
indeed had kinase activity against ERK2. Thus, further investigation is
necessary to gain a deeper understanding of the relationship between
the protein structure and enzymatic activity of MFAP3L, as our ﬁndings
may reveal a novel catalytic domain that differs from that of known
kinases. Furthermore, our bioinformatic analysis indicated that there is
a conserved SH2 motif with a potential EGFR phosphorylation site at
Tyr287. This theoretical analysis correlated with the experimental
evidence described above, in which nuclear-translocated EGFR phos-
phorylatedMFAP3L at Tyr287 and activated its kinase activity. Together,
these ﬁndings suggest that MFAP3L is a novel mediator of EGFR nuclear
signaling.
According to previous studies, certain transcription factors (TFs) can
be phosphorylated by different kinases, leading to their shuttling
between the cytoplasmic and nuclear compartments. For example,
similar to the cytoplasmic kinase PKA, the nuclear kinase MSK1 is also
1432 X. Lou et al. / Biochimica et Biophysica Acta 1842 (2014) 1423–1432able to phosphorylate NFκB at Ser276 upon TNF stimulation, and this
phosphorylation results in the selective transcriptional activation of
NFκB [22]. It is also well known that cytoplasmic ERK is activated by
the RAS/RAF pathway through the phosphorylation of certain threonine
and tyrosine residues in its TXYmotif [16]. Phosphorylated ERK translo-
cates to the nucleus and, in turn, activates downstream TFs, such as
ELK1 and c-fos. Consequently, the overexpression of certain genes
promotes cell proliferation, survival and invasion [16,18]. The nuclear
export of dephosphorylated ERK is dependent on the dephosphoryla-
tion process regulated by the speciﬁc phosphatase MKP in the nucleus
[23]. The rapid turnover of phosphorylation and dephosphorylation
thus results in the dynamic shuttling of ERK between the nuclear and
cytoplasmic compartments [24]. In this study, we introduce a novel nu-
clear kinase, MFAP3L, which may play an active role in the phosphory-
lation of nuclear ERK at Thr185 and Tyr187. Under EGF stimulation,
MFAP3L was phosphorylated and activated, and activated MFAP3L fur-
ther reacted with nuclear ERK2. Consequently, these chain phosphory-
lations may alter ERK2 shuttling and impact cell survival and invasion.
With this kinase activity of MFAP3L, ERK phosphorylation and function
would be expected to be more efﬁcient. Therefore, identiﬁcation of
MFAP3L localization as well as its function is likely to unveil an alterna-
tive activation system of ERK in the nucleus and offer clues regarding
how this nuclear kinase regulates transcription. Although there are
many reports regarding the translocation of EGFR into the nucleus in a
ligand-dependent manner [25,26] and showing that this translocation
is accompanied by gene expression resulting in phenotypic changes in
cancer cells [11,13], the molecular mechanisms underlying this process
are extremely limited but are either related to nuclear import or nuclear
signal transduction [12,26]. Based on our observations, activation of the
MFAP3L kinase likely helps to regulate multiple functions of nuclear-
translocated EGFR in colon cancer cells. The accumulated EGFR in the
nucleus directly phosphorylatesMFAP3L at Tyr287, and phosphorylated
MFAP3L transduces the activation signal to its substrate ERK2, subse-
quently promoting cancer cell invasion andmetastasis. As a novelmedi-
ator, MFAP3L directly connects EGFR to the downstream ERK pathway
in the nucleus without detouring through other pathways, such as the
classical RAS/RAF/MEK pathway. Therefore, the coupling of signaling
transduction between EGFR and MFAP3L constitutes an alternative
activation system for ERK in the nucleus, which regulates tumor
progression and differs from that of the cytoplasmic EGFR pathway.
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